Mumbai, Jul 19 :Zydus Cadila has commercially launched its Mesalamine Delayed Release Tablets USP, 1.2g in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda and is currently the only generic available to patients in the US, company said in a filing with BSe The drug is indicated for the treatment of mild to moderate ulcerative colitis which affects approximately 700,000 people within the US. The group has received 26 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. UNI
Post A Comment:
0 comments so far,add yours